Zentalis Pharmaceuticals Presents Promising Study Results at ASCO

Zentalis Pharmaceuticals ( (ZNTL) ) has shared an announcement.

Zentalis Pharmaceuticals presented data at the 2025 ASCO Annual Meeting regarding a Phase 1 study of azenosertib in combination with encorafenib and cetuximab for metastatic colorectal cancer patients with BRAFV600E mutation. The study, conducted with 44 patients, aimed to assess safety, tolerability, and preliminary antitumor activity. The results indicated a manageable safety profile with no new safety signals at the maximum tolerated dose. The most common treatment-related adverse events were asthenia and decreased appetite. The study found that the combination therapy showed potential efficacy, particularly in BRAF inhibitor-naïve patients, with an overall response rate of 35%.

The most recent analyst rating on (ZNTL) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Zentalis Pharmaceuticals stock, see the ZNTL Stock Forecast page.

Spark’s Take on ZNTL Stock

According to Spark, TipRanks’ AI Analyst, ZNTL is a Neutral.

Zentalis Pharmaceuticals faces significant financial hurdles, with consistent losses and negative cash flows. Technical indicators also show weak momentum. However, recent positive clinical developments provide a glimmer of hope for future growth. Despite the financial and technical challenges, the potential of azenosertib in treating aggressive cancers could offer strategic value, albeit with high risk.

To see Spark’s full report on ZNTL stock, click here.

More about Zentalis Pharmaceuticals

Average Trading Volume: 799,877

Technical Sentiment Signal: Strong Sell

Current Market Cap: $87.06M

See more data about ZNTL stock on TipRanks’ Stock Analysis page.